Yun Zhong
Stock Analyst at Wedbush
(4.03)
# 565
Out of 5,157 analysts
49
Total ratings
58.14%
Success rate
11.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Maintains: Outperform | $33 → $35 | $13.75 | +154.55% | 4 | Mar 6, 2026 | |
| MNKD MannKind | Maintains: Outperform | $10 → $8 | $2.61 | +206.51% | 1 | Mar 5, 2026 | |
| ASND Ascendis Pharma | Maintains: Outperform | $240 → $273 | $240.52 | +13.50% | 4 | Feb 12, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $32 → $34 | $17.66 | +92.53% | 13 | Jan 23, 2026 | |
| RZLT Rezolute | Maintains: Neutral | $1 → $2 | $3.21 | -37.69% | 2 | Jan 8, 2026 | |
| KROS Keros Therapeutics | Maintains: Neutral | $15 → $16 | $11.58 | +38.17% | 3 | Nov 6, 2025 | |
| IRD Opus Genetics | Initiates: Outperform | $8 | $4.85 | +64.95% | 1 | Oct 29, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Outperform | $70 → $86 | $97.05 | -11.39% | 3 | Oct 28, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Outperform | $80 → $18 | $18.34 | -1.85% | 2 | Sep 30, 2025 | |
| PASG Passage Bio | Maintains: Outperform | $3 → $40 | $8.51 | +370.04% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $5.53 | +406.33% | 1 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $8 | $5.00 | +60.00% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $6.05 | +32.23% | 1 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 | $5.30 | +503.77% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $28 | $4.64 | +503.45% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.57 | - | 2 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $14.36 | +11.42% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $18.26 | +151.92% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.40 | +2,401.88% | 1 | May 5, 2021 |
Wave Life Sciences
Mar 6, 2026
Maintains: Outperform
Price Target: $33 → $35
Current: $13.75
Upside: +154.55%
MannKind
Mar 5, 2026
Maintains: Outperform
Price Target: $10 → $8
Current: $2.61
Upside: +206.51%
Ascendis Pharma
Feb 12, 2026
Maintains: Outperform
Price Target: $240 → $273
Current: $240.52
Upside: +13.50%
Sarepta Therapeutics
Jan 23, 2026
Maintains: Outperform
Price Target: $32 → $34
Current: $17.66
Upside: +92.53%
Rezolute
Jan 8, 2026
Maintains: Neutral
Price Target: $1 → $2
Current: $3.21
Upside: -37.69%
Keros Therapeutics
Nov 6, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $11.58
Upside: +38.17%
Opus Genetics
Oct 29, 2025
Initiates: Outperform
Price Target: $8
Current: $4.85
Upside: +64.95%
Protagonist Therapeutics
Oct 28, 2025
Maintains: Outperform
Price Target: $70 → $86
Current: $97.05
Upside: -11.39%
MoonLake Immunotherapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $80 → $18
Current: $18.34
Upside: -1.85%
Passage Bio
Aug 13, 2025
Maintains: Outperform
Price Target: $3 → $40
Current: $8.51
Upside: +370.04%
Aug 11, 2025
Initiates: Outperform
Price Target: $28
Current: $5.53
Upside: +406.33%
Aug 7, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $5.00
Upside: +60.00%
May 27, 2025
Initiates: Outperform
Price Target: $8
Current: $6.05
Upside: +32.23%
May 16, 2025
Reiterates: Outperform
Price Target: $32
Current: $5.30
Upside: +503.77%
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $4.64
Upside: +503.45%
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $4.57
Upside: -
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $14.36
Upside: +11.42%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $18.26
Upside: +151.92%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $0.40
Upside: +2,401.88%